Trial Profile
Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Radium 223 chloride (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Adverse reactions
- 15 Mar 2019 Status changed from active, no longer recruiting to completed.
- 21 May 2018 Interim results (n=39) presented at the 113th Annual Meeting of the American Urological Association.
- 27 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2019.